von Bonin, Frederike

[["dc.bibliographiccitation.firstpage","179"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","180"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Wulf, Gerald G."],["dc.contributor.author","Sadowski, B."],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T08:55:05Z"],["dc.date.available","2018-11-07T08:55:05Z"],["dc.date.issued","2005"],["dc.identifier.doi","10.1038/sj.bmt.1705019"],["dc.identifier.isi","000230244800015"],["dc.identifier.pmid","15937509"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22824"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","0268-3369"],["dc.title","Bone marrow side population (SP) cells are donor derived after allogeneic stem cell transplantation in humans"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Linke, F."],["dc.contributor.author","Zaunig, S."],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Wilting, J."],["dc.contributor.author","Bryja, V."],["dc.contributor.author","Pukrop, Tobias"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Kube, Dieter"],["dc.date.accessioned","2018-11-07T09:50:39Z"],["dc.date.available","2018-11-07T09:50:39Z"],["dc.date.issued","2015"],["dc.format.extent","211"],["dc.identifier.isi","364268800509"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35748"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Wnt5a signaling mediates cell migration and invasion of Hodgkin Lymphoma in vitro and in xenograft models"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3637"],["dc.bibliographiccitation.issue","13"],["dc.bibliographiccitation.journal","Clinical Cancer Research"],["dc.bibliographiccitation.lastpage","3647"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Heemann, Christina"],["dc.contributor.author","Kreuz, Markus"],["dc.contributor.author","Stoller, Irene"],["dc.contributor.author","Schoof, Nils"],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Kube, Dieter"],["dc.date.accessioned","2018-11-07T09:08:22Z"],["dc.date.available","2018-11-07T09:08:22Z"],["dc.date.issued","2012"],["dc.description.abstract","Purpose: Peripheral T-cell non-Hodgkin lymphomas (T-NHL) represent a small but heterogeneous and clinically aggressive subset of NHLs with a poor outcome. Cytokines or their receptors might be associated with the clinical outcome of these lymphomas. Therefore, we tested whether gene variations and serum levels of soluble TNF receptor (TNFR)I (sTNFRI), sTNFRII, interleukin (IL)-10, or sIL-4R are predictive for treatment response in T-NHLs. Experimental Design: Peripheral blood DNA from 117 patients with T-NHL treated in prospective clinical trials was subjected to genotyping analysis. Whenever possible, pretreatment sera were obtained, and circulating levels of sTNFRI, sTNFRII, IL-10, and sIL-4R were determined with a specific capture enzyme-linked immunoassay. Results: Patients characterized by TNFRI-609GG (rs4149570) showed a trend toward better event free survival [EFS; univariate: P = 0.041; multivariate: HR, 1.76; confidence interval (CI), 0.99-3.14 with P = 0.056]. A protective role of IL-10-1087A, -824T, and -597A reported in another study was not confirmed in our cohort. Patients with circulating levels of soluble TNFRII >= 2.16 ng/mL had a 2.07-fold increased relative risk for shorter overall survival (OS; univariate: P = 0.0034; multivariate: HR, 2.07; CI, 0.92-4.70 with P = 0.081) and a 2.49-fold higher risk for shorter EFS (univariate: P = 0.00068; multivariate: HR, 2.49; CI, 1.22-5.08 with P = 0.012). Elevations of circulating levels of sTNFRI, IL-10, and sIL-4R are frequent, but the clinical response in these patients is not significantly different. Conclusions: Our findings suggest a critical role for TNF-TNFR signaling for the clinical outcome of patients with peripheral T-NHLs. Clin Cancer Res; 18(13); 3637-47. (C)2012 AACR."],["dc.identifier.doi","10.1158/1078-0432.CCR-11-3299"],["dc.identifier.isi","000307502600016"],["dc.identifier.pmid","22573350"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26018"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.relation.issn","1078-0432"],["dc.title","Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non-Hodgkin Lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","586"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Genes and Immunity"],["dc.bibliographiccitation.lastpage","590"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Schoof, Nils"],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Koenig, Inke R."],["dc.contributor.author","Moessner, R."],["dc.contributor.author","Krueger, Ulrich"],["dc.contributor.author","Reich, Kristian"],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Volkenandt, Matthias"],["dc.contributor.author","Ziegler, Andreas"],["dc.contributor.author","Boeckmann, L."],["dc.contributor.author","Kuschal, Christiane"],["dc.contributor.author","Thoms, K-M"],["dc.contributor.author","Kube, Dieter"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T11:24:52Z"],["dc.date.available","2018-11-07T11:24:52Z"],["dc.date.issued","2009"],["dc.description.abstract","Inherited promoter polymorphisms of the interleukin (IL)-10 gene resulting in altered IL-10 production may contribute to a genetic susceptibility for melanoma. We investigated the role of a haplotype from distal as well as proximal polymorphic sites [-7400InDel, -6752AT (rs6676671), -3538AT (rs1800890), -1087AG (rs1800896), -597AC (rs1800872)] of the IL-10 5'-flanking region in a hospital-based case-control study of 165 Caucasian patients with cutaneous melanoma from Germany in comparison with 162 healthy cancer-free Caucasian control participants from the same area matched by age. Using multivariate analysis for the number of nevi and skin type, the IL-10 'higher producing' haplotype ITAGC was found to be significantly associated with a reduced risk of developing melanoma ( adjusted P = 0.02). Although our findings need to be confirmed by independent and larger multicenter studies, we have described for the first time the association of distal gene variants of the IL-10 gene as an independent risk factor for melanoma. Genes and Immunity ( 2009) 10, 586-590; doi:10.1038/gene.2009.40; published online 21 May 2009"],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft DFG [GRK1034]"],["dc.identifier.doi","10.1038/gene.2009.40"],["dc.identifier.isi","000269493400005"],["dc.identifier.pmid","19458621"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56507"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","1466-4879"],["dc.title","Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case-control study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Annals of Human Genetics"],["dc.bibliographiccitation.volume","76"],["dc.contributor.author","Viktorova, Elena"],["dc.contributor.author","Malzahn, Doerthe"],["dc.contributor.author","Balavarca, Yesilda"],["dc.contributor.author","Isernhagen, Antje"],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Michael, Janne"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Kube, Dieter"],["dc.contributor.author","Dressel, Ralf"],["dc.contributor.author","Bickeboeller, Heike"],["dc.date.accessioned","2018-11-07T09:06:11Z"],["dc.date.available","2018-11-07T09:06:11Z"],["dc.date.issued","2012"],["dc.format.extent","433"],["dc.identifier.isi","000307377000064"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25495"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","European Mathematical Genetics Meeting"],["dc.relation.eventlocation","Gottingen, GERMANY"],["dc.relation.issn","0003-4800"],["dc.title","Association of MICA-129 genotype with common risks of hematopoietic stem cell transplantation (HSCT)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Experimental Dermatology"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Schoof, Nils"],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Koenig, Inke R."],["dc.contributor.author","Moessner, R."],["dc.contributor.author","Krueger, Ulrich"],["dc.contributor.author","Reich, Kristian"],["dc.contributor.author","Ziegler, Andreas"],["dc.contributor.author","Boeckmann, L."],["dc.contributor.author","Kuschal, Christiane"],["dc.contributor.author","Thoms, Kai Martin"],["dc.contributor.author","Kube, Dieter"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T08:32:01Z"],["dc.date.available","2018-11-07T08:32:01Z"],["dc.date.issued","2009"],["dc.format.extent","284"],["dc.identifier.isi","000263520200070"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17251"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell Publishing, Inc"],["dc.publisher.place","Malden"],["dc.relation.conference","36th Annual Meeting of the Arbeitsgemeinschaft-Dermatologishche-Forschung"],["dc.relation.eventlocation","Heidelberg, GERMANY"],["dc.relation.issn","0906-6705"],["dc.title","Distal and proximal interleukin-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case-control study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","13"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Oncogene"],["dc.bibliographiccitation.lastpage","23"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Linke, F."],["dc.contributor.author","Zaunig, S."],["dc.contributor.author","Nietert, M. M."],["dc.contributor.author","Bonin, F. von"],["dc.contributor.author","Lutz, S."],["dc.contributor.author","Dullin, C."],["dc.contributor.author","Janovská, P."],["dc.contributor.author","Beissbarth, T."],["dc.contributor.author","Alves, F."],["dc.contributor.author","Klapper, W."],["dc.contributor.author","Bryja, V."],["dc.contributor.author","Pukrop, T."],["dc.contributor.author","Trümper, L."],["dc.contributor.author","Wilting, J."],["dc.contributor.author","Kube, D."],["dc.date.accessioned","2018-10-19T06:32:50Z"],["dc.date.available","2018-10-19T06:32:50Z"],["dc.date.issued","2017"],["dc.description.abstract","Classical Hodgkin lymphoma (cHL) has a typical clinical manifestation, with dissemination involving functionally neighboring lymph nodes. The factors involved in the spread of lymphoma cells are poorly understood. Here we show that cHL cell lines migrate with higher rates compared with non-Hodgkin lymphoma cell lines. cHL cell migration, invasion and adhesion depend on autocrine WNT signaling as revealed by the inhibition of WNT secretion with the porcupine inhibitors Wnt-C59/IWP-2, but did not affect cell proliferation. While application of recombinant WNT5A or WNT5A overexpression stimulates HL cell migration, neither WNT10A, WNT10B nor WNT16 did so. Time-lapse studies revealed an amoeboid type of cell migration modulated by WNT5A. Reduced migration distances and velocity of cHL cells, as well as altered movement patterns, were observed using porcupine inhibitor or WNT5A antagonist. Knockdown of Frizzled5 and Dishevelled3 disrupted the WNT5A-mediated RHOA activation and cell migration. Overexpression of DVL3-K435M or inhibition of ROCK (Rho-associated protein kinase) by Y-27632/H1152P disrupted cHL cell migration. In addition to these mechanistic insights into the role of WNT5A in vitro, global gene expression data revealed an increased WNT5A expression in primary HL cells in comparison with normal B-cell subsets and other lymphomas. Furthermore, the activity of both porcupine and WNT5A in cHL cells had an impact on lymphoma development in the chick chorionallantoic membrane assay. Massive bleeding of these lymphomas was significantly reduced after inhibition of WNT secretion by Wnt-C59. Therefore, a model is proposed where WNT signaling has an important role in regulating tumor-promoting processes."],["dc.fs.pkfprnr","66887"],["dc.identifier.doi","10.1038/onc.2016.183"],["dc.identifier.fs","626468"],["dc.identifier.pmid","27270428"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16088"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1476-5594"],["dc.title","WNT5A: a motility-promoting factor in Hodgkin lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","80"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","The Oncologist"],["dc.bibliographiccitation.lastpage","89"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Schoof, Nils"],["dc.contributor.author","Franklin, Jeremy"],["dc.contributor.author","Fuerst, Robert"],["dc.contributor.author","Zander, Thomas"],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Peyrade, Frederic"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Diehl, Volker"],["dc.contributor.author","Engert, Andreas"],["dc.contributor.author","Kube, Dieter"],["dc.contributor.author","Re, Daniel"],["dc.date.accessioned","2018-11-07T09:30:24Z"],["dc.date.available","2018-11-07T09:30:24Z"],["dc.date.issued","2013"],["dc.description.abstract","Background. Hodgkin lymphoma (HL) is a lymphoid malignancy characterized by the production of various cytokines possibly involved in immune deregulation. Interleukin-10 (IL-10) serum levels have been associated with clinical outcome in patients with HL. Because host genetic variations are known to alter the expression and function of cytokines and their receptors, we investigated whether genetic variations influence clinical outcome of patients with HL. Methods. A total of 301 patients with HL who were treated within randomized trials by the German Hodgkin Study Group were included in this exploratory retrospective study. Gene variations of IL-10 (IL-10(-597AC), rs1800872; IL-10(-824CT), rs1800871; IL-10(-1087AG), rs1800896; IL-10(-3538AT), rs1800890; IL-10(-6208CG), rs10494879; IL-10(-6752AT), rs6676671; IL-10(-7400InDel)), IL-13 (IL-13(-1069CT), rs1800925; IL-13(Q144R), rs20541), and IL-4R (IL-4R(I75V), rs1805010; IL-4R(Q576R), rs1801275) were genotyped. Results. Inferior freedom from treatment failure (FFTF) was found in patients harboring the IL-10(-597AA), IL-10(-824TT), or the IL-10(-1087AA) genotype. In contrast, the IL-10(-1087G-824C-597C) haplotype present in about 48% of analyzed HL patients is nominally significant for a better FFTF in a Cox-Regression model accounting for stage and treatment. No associations were observed between the other IL-10 gene variations, IL-13(-1069CT), IL-13(Q144R), IL-4R(I75V), IL-4R(Q576R) and the clinical outcome of patients with HL. Conclusions. Our study provides further evidence that proximal IL-10 promoter gene variations are associated with clinical course of patients with HL. However, treatment success and survival rates are already at a very high rate, supporting the need to design studies focusing on identification of predictors to reduce the side effects of therapy. The Oncologist 2013;18:80-89"],["dc.identifier.doi","10.1634/theoncologist.2012-0291"],["dc.identifier.isi","000314703200017"],["dc.identifier.pmid","23299779"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31300"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Alphamed Press"],["dc.relation.issn","1083-7159"],["dc.title","Interleukin-10 Gene Polymorphisms are Associated With Freedom From Treatment Failure for Patients With Hodgkin Lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","78"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","European Journal Of Haematology"],["dc.bibliographiccitation.lastpage","84"],["dc.bibliographiccitation.volume","75"],["dc.contributor.author","Schroers, Roland"],["dc.contributor.author","Hildebrandt, Y."],["dc.contributor.author","Steffens, Rainer"],["dc.contributor.author","Becker, S."],["dc.contributor.author","Ohms, G."],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Bertsch, Hans-Peter"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T09:05:40Z"],["dc.date.available","2018-11-07T09:05:40Z"],["dc.date.issued","2005"],["dc.description.abstract","Mantle cell lymphoma (MCL) is immunophenotypically characterized by cell surface co-expression of CD19, CD20, CD5, IgM and FMC7. However, the concomitant presence of other antigens distinctive of a particular leukocyte subset, e.g. T-lymphocytes, is an exceptional finding in MCL. Here, the first case of a blastic MCL in leukaemic phase with aberrant expression of the T-cell associated antigen CD8 occurring in a patient with concomitant Mycosis fungoides is described. Comprehensive immunophenotypic analysis showed that the MCL cells expressed the typical B-lymphocytic markers, were CD5 and CD8 positive, but did not express other T-cell proteins, such as CD2, CD3, CD4, CD7, TCRαβ and TCRγδ. The MCL cells expressed both CD8α and CD8β chains indicating cell surface presence of CD8αβ heterodimers. Intriguingly, expression of the cytotoxic enzymes perforin and granzyme A was detected by RT-PCR. Cytogenetic and molecular genetic analysis of the lymphoma cells confirmed cyclin D1 overexpression secondary to the t(11;14)(q13;32) chromosomal translocation. Furthermore, trisomy 11, trisomy 14 and extra copies of t(11;14) translocated chromosomes were detected in sub clones of the analyzed MCL cells. Clinically, an aggressive course of disease including cerebral lymphoma involvement was noted in the reported patient. Hence, systematic studies addressing the incidence, biology and clinical behavior of this form of MCL seem to be justified in future."],["dc.identifier.doi","10.1111/j.1600-0609.2005.00432.x"],["dc.identifier.isi","000229581400013"],["dc.identifier.pmid","15946316"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25379"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing"],["dc.relation.issn","0902-4441"],["dc.title","Immunophenotypic and genetic characterization of a CD8 positive Mantle Cell Lymphoma in a patient with concomitant Mycosis Fungoides"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3777"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Clinical Cancer Research"],["dc.bibliographiccitation.lastpage","3784"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Kube, Dieter"],["dc.contributor.author","Hua, Thanh-Duc"],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Schoof, Nils"],["dc.contributor.author","Zeynalova, Samira"],["dc.contributor.author","Kloess, Marita"],["dc.contributor.author","Gocht, Daniela"],["dc.contributor.author","Potthoff, Bernd"],["dc.contributor.author","Tzvetkov, Mladen"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T11:13:57Z"],["dc.date.available","2018-11-07T11:13:57Z"],["dc.date.issued","2008"],["dc.description.abstract","Purpose: Current chemotherapy can achieve high response rates in aggressive non-Hodgkin's lymphoma (NHL), but the factors that influence regression and survival remain unknown. The present exploratory study tested the hypothesis whether interleukin-10 (IL-10) polymorphisms predict clinical outcome, leukocytopenia, or infectivity during therapy. IL-10 was chosen because immune alterations area major risk factor for NHL, and IL-10 is a cytokine involved in inflammatory processes associated with clinical outcome. Experimental Design: Five hundred patients with aggressive NHL treated with CHOP/CHOEP were analyzed for IL-10 gene polymorphisms, including distal loci -7400InDel, -6752AT (rs6676671), and -6208CG (rs10494879) in comparison with proximal loci -3538AT (rs1800890), -1087AG (rs1800896), and -597AC (rs1800872) according to the incidence and outcome of the lymphoma. Results: No differences in allele frequencies or haplotypes were found comparing a cohort of patients with aggressive NHL/diffuse large B-cell lymphoma with a healthy control group. Patients with aggressive NHL characterized by IL-10(-7400DelDel) had shorter overall survival periods compared with the other genotypes (P = 0.004). The 3-year rate is 43.4% for IL-10(-7400DelDel) and 73.4% for IL-10(-7400InIn) and IL-10(-7400InDel) together. A significant increased risk for event-free survival is found for carriers of the genotype IL-10(-6752TT-6208CC-3538AA) (P = 0.047). Multivariate analysis of IL-10(-7400) gene variation in relation to overall survival adjusted to international prognostic index revealed a relative risk of 1.9 for carriers of IL-10(-7400DelDel) (P = 0.037). No associations were found analyzing diffuse large B-cell lymphoma patients separately. Conclusion: Our results indicate that IL-10 gene variations could be associated to the clinical course of aggressive NHL, which points out the importance of host factors and respective genetic elements for treatment response."],["dc.identifier.doi","10.1158/1078-0432.CCR-07-5182"],["dc.identifier.isi","000256779100022"],["dc.identifier.pmid","18559596"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54018"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.relation.issn","1078-0432"],["dc.title","Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: An exploratory study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]